FAQs - SoRCE Questions_6.11.26.pdf
PDF 55 KB Posted
- Opportunity number
- HRSA-26-052
About this file
This is a Frequently Asked Questions (FAQs) document for HRSA 26-052, the Sickle Cell Disease Regional Care Excellence (SoRCE) Program. The funding opportunity has a four-year project period beginning September 1, 2026, and ending August 31, 2030. Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs), where each CCS comprises one clinical center partnered with at least one community-based organization (CBO). The minimum three CCSs must account for at least 40% of the total budget, with remaining funds available to support other clinical sites in the region without CBO partnerships. Subawards and agreements do not need to be established before application submission; Letters of Support or Memoranda of Understanding that describe roles and deliverables are acceptable. Within six months of award, the RCH must develop a regional action plan to support partnership, collaboration, and resource sharing across all CCSs in the region.
The SoRCE emerging issues supplement is available as a one-time, one-year award of up to $250,000 per year, which may be awarded in any of the four project years based on fund availability and appropriation. Supplement applications must be included with the initial application, and supplements are funded in order of the objective review scores earned in the base competition. The emerging issues supplement does not count toward the application page limit. Review panels will assess how well applications describe plans to reach every person with sickle cell disease in the region through the required CCSs.
FAQs - SoRCE Questions_6.11.26.pdf
View the file
Other files
| File | Type | Posted |
|---|---|---|
| FAQs HRSA-26-052.pdf | ||
| HRSA-26-052 TA Call Presentation.pdf | ||
| FAQs -HRSA-26-052.pdf | ||
| HRSA-26-052 Final.pdf | ||
| HRSA-26-052 Final.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
FAQs – Sickle Cell Disease Regional Care Excellence Program (SoRCE)
HRSA 26-052
Q: What is the project period for HRSA 26-052, the Sickle Cell Disease Regional Care Excellence (SoRCE) Program funding opportunity?
A: The project period is four years, starting on 9/1/2026 and ending on 8/31/2030.
Q: Can one CBO partner with three other clinical sites to meet the Clinical Community Spoke (CCS) requirements for the region?
A: See page 5 of the NOFO (see Program Structure section): Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs) in their region. Each CCS includes one clinical center partnered with at least one community-based organization (CBO).
See page 39 of the NOFO: The panel reviewing NOFO applications will look to see how well applications describe plans to reach every person with Sickle Cell Disease (SCD) in the region through at least three CCSs.
Q: Do subawards have to be established before our application is submitted?
A: No. If you include documents that confirm actual or pending contracts or agreements (e.g., Letter of Support, Memorandum of Understanding, etc.), the documents should clearly describe the roles of subrecipients and contractors and any deliverables. It is not necessary to include the entire contents of lengthy agreements, so long as the portions you include describe the working relationship between you and the other (See pg. 34 of the NOFO under Attachment 5 for more information).
Please note that within six months, the RCH must develop a regional action plan to support partnership, collaboration, and resource sharing across all CCSs in the region. (See page 13 of the NOFO).
Q: Does the SoRCE emerging issues supplement count towards the page limit?
A: No. The SoRCE emerging issues supplement does not count towards the page limit.
Please see page 24 of the NOFO for the list of items that are included in the page limit.
Q: How is the supplement awarded?
A: Depending on the availability and appropriation of funds, supplemental funding may be awarded in any of the four project years. If applicants are interested in receiving supplemental funds, they must include their supplement application as part of their initial application. These are one timeone-time, one-year supplements for up to $250,000 per year. Supplements will be funded in the order of the objective review score earned by the applicant in the base competition. Please see page 34 of the NOFO for more information.
https://www.grants.gov/search-results-detail/360997 https://www.grants.gov/search-results-detail/360997 https://www.grants.gov/search-results-detail/360997
Q: After meeting the CCS requirement to contract with at least three Clinical- Community Spokes (CCSs) in the region, can we provide funds to clinical sites in our region that do not have a partnership with a CBO?
A: Yes. See page 5 of the NOFO (see Program Structure section): Each Regional Coordinating Hub (RCH) must contract with at least three Clinical-Community Spokes (CCSs) in their region. After meeting the requirement to have contracts with at least 3 CCCs in your region accounting for at least 40% of your budget, the remaining part of your budget can support other clinical sites in your region that do not have a partnership with a Community-Based Organization (CBO).
File details come from the government source that posted it. Updated .